Introduction: Rhabdomyomas are benign tumors of striated muscle, the bladder localization is very rare. Clinical Case: We present an 87-year-old male consulting for gross hematuria. Cystoscopy was done with evidence of bulged bladder mucosa in right side wall and dome. Post-transurethral resection of the bladder (TURB) pathological anatomy was negative for malignancy. As extension study abdominopelvic computed tomography was performed identifying a bladder thickening of right posterior sidewall and an increased density of the adjacent fat. Second TURB was performed and a fetal bladder rhabdomyoma intermediate type was obtained. We performed another biopsy to confirm this rare pathology, with the same diagnosis. Subsequently, the patient continues with hematuria deciding on hemostatic radiotherapy (not candidate for cystectomy or arterial embolization). Currently, the patient is asymptomatic. Discussion: Bladder rhabdomyomas are rare tumors, and, in fact, there have been only 5 papers published. Some cases are only isolation cited in the bladder mesenchymal tumors, and other polemic cases in which clinical and macroscopic characteristics remembered a rhabdomyosarcoma. The importance of this publication case is the macro- and microscopic images that can corroborate the final diagnosis, helping us to differentiate between rhabdomyoma, rhabdomyofibroma, or the malignant rhabdomyosarcoma, and shows the treatment possibilities of these tumors.

Keywords:
Rhabdomyoma, Bladder tumor, Hematuria, Radiotherapy , Radical cystectomy
1.
Weiss SW, GoldBlum JR: Enzinger and Weiss Soft Tissue Tumors. Chapter 21. Rabdomyoma, ed 4. Mosby, St Louis, London, Philadelphia, 2001, pp 769–779 .
2.
Kempson RL, et al: Tumors of the soft tissues: Atlas of Tumor Phatology, ed 3. AFIP. Washington, 2001, pp 257–262.
3.
Hautmann S, Felix-Chun KH, Currlin E, Friedrich MG, et al: Cystectomy for indications other than bladder cancer. Urologe A 2004; 43: 172–177.
4.
Kunze, E, Yheuring F, Küger G: Primary mesenchymal tumors of the urinary bladder. A histological and immunohistochemical study of 30 cases. Pathol Res Pract 1994; 190: 311–332.
5.
Szadowska, A, Giryn I, Zawadzki R: The value of electron microscopic examination of differential diagnosis of fetal rhabdomyoma and embryonal rhabdomyosarcoma of urinary bladder. Acta Med Pol 1979; 20: 459–460.
6.
Hanbury WJ: Rhabdomyomatous tumours of the urinary bladder and prostate. J Pathol Bacteriol 1952; 64: 763–773.
7.
Shattock SG: Rhabdomyoma of the urinary bladder. Proc R Soc Med 1910; 3(pathol sect):31–41.
8.
Lange J, Etcheverry M, Lange D: Rhabdomyofibroma of the bladder or rhabdomyosarcoma?. J Urol Nephrol (Paris) 1967; 73: 747–754.
9.
Beverly RR, et al: The Intergroup Rhabdomyosarcoma Study Group (IRSG): major lessons from the IRS-I through IRS-IV studies as background for the current IRS-V treatment protocols. Sarcoma 2001; 5: 9–15.
10.
Heyn R, et al: Preservation of the bladder in patients with rhabdomyosarcoma. J Clin Oncol 1997; 15: 69–75.
11.
Castagnetti M, et al: Oncologic outcome and urinary function after radical cystectomy for rhabdomyosarcoma in children: role of the orthotopic ideal neobladder based on 15-year experience at a single Center. J Uro 2014; 191: 1850–1855.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.